ArriVent BioPharma Target Price

Where could AVBP trade next? Consensus target price: $46.

Get informed when a big investor buys or sells

+ Follow

Share Price

$28.57

Average Target Price

$46.00

61% upside

2 analysts in the last 4 months

High: $47 | Low: $45

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-17	H.C. Wainwright	$47	64.5% upside
2026-05-29	Truist Financial	$45	57.5% upside
2025-12-10	BTIG	$45	57.5% upside
2025-11-25	Truist Financial	$43	50.5% upside
2025-07-10	Goldman SachsCorinne Johnson	$33	15.5% upside
2024-09-10	CitigroupYigal Nochomovitz	$36	26% upside
2024-09-10	H.C. WainwrightRobert Burns	$36	26% upside
2024-08-16	H.C. WainwrightRobert Burns	$30	5% upside
2024-07-22	OppenheimerJeff Jones	$35	22.5% upside

ArriVent BioPharma (AVBP) FAQ

ArriVent BioPharma (AVBP) currently reports a target price of $46. Use the charts on this page to explore ArriVent BioPharma's target price history and peer comparisons.

Analysts' average 12-month price target for ArriVent BioPharma is $46, about 61.0% upside from the current share price of $28.57. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $46, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ArriVent BioPharma, and consider following AVBP for alerts when major investors trade the stock.